Equity Profile

CRL

Charles River Laboratories International, Inc.

Health CareLife Sciences Tools & Services$13.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if CRL meets or exceeds expectations.

$2.74

Revenue

Total revenue gives insight into the company's sales performance and market demand for its services, which is critical for growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in supporting the pharmaceutical and biotechnology industries by providing essential services for drug development and testing.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1 2026, CRL reported an EPS of $2.06, exceeding estimates by 5.21%. However, there was no revenue figure reported, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CRL to report solid earnings, with a consensus EPS of $2.74 and revenue of $977M. The market is closely watching for any signs of growth or challenges.

Bull Case

If CRL can deliver strong earnings and positive commentary on future growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could result in a decline in stock price.

Key Metrics to Watch

EPS

$2.74

Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if CRL meets or exceeds expectations.

Revenue

$977M

Total revenue gives insight into the company's sales performance and market demand for its services, which is critical for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRL's EPS exceed the consensus estimate of $2.74?

A beat on EPS could signal strong operational performance and boost investor confidence.

What is the outlook for revenue growth given the current market conditions?

Understanding revenue trends will help investors gauge demand for CRL's services and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CRL's ability to capitalize on increased demand for life sciences services, especially in drug development.

Supporting Evidence

CRL has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility, which could be driven by positive news.

Recent trends in the life sciences sector show increased investment, which could benefit CRL.

Key Risk

If CRL's revenue growth significantly outpaces expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRL can sustain its growth trajectory amidst competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $2.80 or higher would confirm the bull case and indicate strong demand.

Bear Confirmed If

An EPS below $2.68 would support the bear case and raise concerns about growth.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests a potential stock increase of around +1.27%, confirming strong operational momentum.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, reflecting uncertainty about future growth.

Miss

If CRL misses estimates, the stock could decline, with historical patterns suggesting a potential drop of around -5.71%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new contracts or partnerships in the life sciences sector.
2Management's commentary on market demand and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Future guidance on revenue growth and potential challenges.
5Any changes in regulatory impacts on the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Charles River Laboratories International, Inc. (CRL) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if CRL meets or exceeds expectations.

$2.74

Revenue

Total revenue gives insight into the company's sales performance and market demand for its services, which is critical for growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1 2026, CRL reported an EPS of $2.06, exceeding estimates by 5.21%. However, there was no revenue figure reported, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CRL to report solid earnings, with a consensus EPS of $2.74 and revenue of $977M. The market is closely watching for any signs of growth or challenges.

Bull Case

If CRL can deliver strong earnings and positive commentary on future growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could result in a decline in stock price.

Key Metrics to Watch

EPS

$2.74

Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if CRL meets or exceeds expectations.

Revenue

$977M

Total revenue gives insight into the company's sales performance and market demand for its services, which is critical for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRL's EPS exceed the consensus estimate of $2.74?

A beat on EPS could signal strong operational performance and boost investor confidence.

What is the outlook for revenue growth given the current market conditions?

Understanding revenue trends will help investors gauge demand for CRL's services and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CRL's ability to capitalize on increased demand for life sciences services, especially in drug development.

Supporting Evidence

CRL has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility, which could be driven by positive news.

Recent trends in the life sciences sector show increased investment, which could benefit CRL.

Key Risk

If CRL's revenue growth significantly outpaces expectations, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRL can sustain its growth trajectory amidst competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $2.80 or higher would confirm the bull case and indicate strong demand.

Bear Confirmed If

An EPS below $2.68 would support the bear case and raise concerns about growth.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests a potential stock increase of around +1.27%, confirming strong operational momentum.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, reflecting uncertainty about future growth.

Miss

If CRL misses estimates, the stock could decline, with historical patterns suggesting a potential drop of around -5.71%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new contracts or partnerships in the life sciences sector.
2Management's commentary on market demand and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Future guidance on revenue growth and potential challenges.
5Any changes in regulatory impacts on the business.